PDF
ePub
Citation
Print
INTRODUCTION
Among many endocrinological causes of secondary osteoporosis (e.g., Cushing's syndrome, hyperparathyroidism, hypogonadism), conditions of excess or deficient thyrotropin (thyroid-stimulating hormone [TSH]) and thyroid hormones are potentially damaging to bone status.[12] Although endogenous hyperthyroidism is associated with an increased risk of osteoporosis due to increased osteoclastic resorption and decreased bone formation,[34] the effect of suppressive thyroxine therapy on osteoporosis remains unclear. Recent concerns have emerged that lifelong TSH-suppressive therapy may have the potentially harmful effects on the heart and skeleton induced by subclinical hyperthyroidism [5] differentiated thyroid cancer (DTC) is the most common endocrine malignancy and is generally an indolent tumor with a 10-year overall survival rate of 80% to 95%.[6]
Osteoporosis is the recent concern regarding lifelong TSH-suppressive therapy.[57891011] Osteoporosis is a major healthcare challenge worldwide; the number of newly diagnosed cases and associated costs of osteoporotic fracture are increasing with age. Both menopause and hyperthyroidism are the risk factor of osteoporosis,[12] and women with hyperthyroidism experience their first fractures earlier during life than do those without.[13] Recent studies reported that, suppressed TSH level is significantly correlated with the risk of osteoporosis after total thyroidectomy.[1415] Osteoporosis is characterized by a low bone mass and microarchitectural deterioration. The World Health Organization's standard criterion for diagnosing osteoporosis uses densitometry tools, such as dual energy X-ray absorptiometry (DXA) for measuring areal bone mineral density (aBMD; mg/cm2) and calculating a T-score. The trabecular bone score (TBS) is a new textural index obtained from DXA, that evaluates pixel gray-level variations of the lumbar spines has recently been proposed as an representative parameter for the trabecular bone microarchitecture independent of BMD.[16] According to recent study, Recuded TBS has association with increased osteoporotic vertebral fractures risk in patients with osteopenia, as well as in those with normal BMD.[17] In healthy euthyroid post-menopausal women, the TBS is negatively correlated with free thyroxine (fT4) levels within range for high-to-normal.[18] In postmenopausal women with DTC, a longer duration of TSH suppression was independently associated with a decreased lumbar spine TBS.[19] From a clinical perspective, the additional information about bone quality provided by the TBS could aid the management of patients with osteopenia, as well as those with normal BMD who have risk factors for osteoporosis.
We designed this retrospective study to determine whether suppressive L-thyroxine (LT4) therapy after a total thyroidectomy influences the TBS, and compare the incidence of osteoporosis with a healthy control group.
METHODS
1. Study subjects
This retrospective study included postmenopausal women with DTC who underwent a total thyroidectomy and began follow-up testing between October 2013 and January 2017 at Hospital. The strict selection criteria for the TSH-suppression group were as follows: (1) no distant metastasis or invasion of locoregional structures; (2) postmenopausal status with a baseline DXA evaluation; (3) treatment with LT4 at suppressive doses to maintain a serum TSH level <0.3 mU/I; (4) fT4 level within the normal range; (5) free of thyroid cancer on clinical and laboratory examinations during follow-up (negative neck ultrasound and undetectable serum thyroglobulin); and (6) regular follow-up visits. Because menopause is a risk factor for osteoporosis, all patients underwent repeat DXA for evaluation of bone mineral density. We enrolled postmenopausal women (n=36) with papillary thyroid cancer who underwent total thyroidectomy and TSH suppression.
2. Healthy control group
To identify the healthy controls, we enrolled postmenopausal women (n=94) who visited our hospital for a health check-up and matched in age and body mass index (BMI) to the treatment group. They had annual checkup for lumbar spine DXA and thyroid function tests (serum TSH, fT4, and T3). The participants in the healthy control group had serum TSH levels within the normal reference range and did not have hypo- or hyperthyroidism or a history of malignant disease. Exclusion criteria for all participants included renal or hepatic impairment and exposure to any medication that affects bone metabolism such as glucocorticoids or anti-osteoporotic drugs.
TSH and fT4 levels were measured using the conventional BRAHMS manual immunoradiometric assay (Thermo Fisher Scientific BRAHMS GmbH, Hennigsdorf, Germany). Laboratory analyses of calcium, phosphate, and alkaline phosphatase levels were performed on the same day as DXA.
This retrospective study was approved by our Institutional Review Board (IRB), which waived the requirement for written consent (IRB No. H-1711-008-061).
3. DXA
The aBMD of the lumbar vertebrae (L1-4) was measured on DXA scans (Lunar Prodigy; GE Medical Systems, Milwaukee, WI, USA) and analyzed using Encore software (version 13.0; GE Healthcare, Madison, WI, USA). Calibration and quality assurance tests were performed daily. The coefficient of variation for precise measurement of the aBMD of the lumbar spine was 0.34%. T-scores were defined according to the number of standard deviations (SDs) from the mean BMD of a reference group from the general population aged 25 to 35 years and matched for sex, as follows: l normal, lowest T-score≥−1.0; osteopenia, −2.5<lowest T-score<−1.0; and osteoporosis, ≤−2.5. The TBS of the lumbar spine was extrapolated from the lumbar spine DXA file using iNsight software (version 3.0.2.0; Medimaps, Merignac, France). A TBS was classified by a cutoff of >1.350 for a normal TBS value according to an international working group of TBS users for postmenopausal women.[20] The ratios of TBS and aBMD deterioration were calculated according to the baseline and final follow-up values.
4. Statistical analyses
All normally distributed variables were expressed as means±SD, while variables with non-normal distributions are expressed as medians and interquartile ranges (IQRs; 25−75%). To compare categorical data between the treatment and control groups, the χ2 test was used. A paired t-test was used to compare the follow-up DXA scans. The Mann-Whitney U test was used to compare the median values of non-normally distributed variables between the treatment and control groups. P-values <0.05 were considered statistically significant. The statistical analyses were performed using both MedCalc® for Windows software (version 16.4.3; MedCalc, Mariakerke, Belgium) and GraphPad Prism® (version 6; GraphPad Software, La Jolla, CA, USA).
RESULTS
1. Patient characteristics
There was no difference in the median follow-up period from the baseline DXA evaluation between the TSH suppression group (4.0±1.7 years) and the control group (4.4±1.7 years; P=0.923). The median age (60.5±5.5 years vs. 60.8±5.5 years, P=0.127) and BMI (23.31±2.77 vs. 23.20±2.93, P=0.356) also did not differ between the TSH suppression and control groups. The TSH-suppressive therapy was maintained for 4.66±1.52 years after total thyroidectomy at the baseline DXA study. The daily dose of LT4 for the patient group was 200 to 750 µg/day or 2.500±0.774 µg/kg. Of the patients in the TSH suppression group, 32 (88.89%) received calcium/vitamin D supplementation. Of the participants in the control group, 34 (36.17%) received calcium/vitamin D supplementation. The TSH levels of all patients in the TSH suppression group were nearly non-detectable (median, 0.000; IQR, 0.000-0.254), whereas those in the control group were within the normal range (median, 1.975; IQR, 1.141–1.644; P<0.001). The fT4 levels of all participants were within the normal range; however, the mean level differed significantly between the TSH suppression group (1.706±0.319) and control group (1.240±0.165; P<0.001). The baseline clinical characteristics of the participants in both groups are shown in Tables 1 and 2.
2. Comparison of DXA results between the TSH suppression and control groups during follow-up
There was no significant difference in the rate of diagnosis of osteoporosis, osteopenia, or normal bone status between the 2 groups during the baseline DXA evaluation (Fig. 1). The average aBMD of the patients who received TSH-suppressive therapy was not significantly different from that of the control group (1st DXA, 0.997±0.149 vs. 1.081±0.148, P=0.415; 2nd DXA, 0.986±0.145 vs. 1.074±0.147, P=0.670; Table 2) and did not change significantly during follow-up (Fig. 2A). The mean TBS at the 1st DXA and follow-up DXA evaluations was significantly lower in patients with TSH suppression than in the control group (1st DXA, 1.344±0.098 vs. 1.372±0.063, P<0.001; 2nd DXA, 1.342±0.095 vs. 1.370±0.062, P<0.001; Table 2) whereas TBS was not significantly changed comparing at baseline and follow-up regardless of TSH suppressive treatment (Fig. 2B). According to the TBS threshold of 1.350, the status of the microarchitecture was not significantly different between the 2 groups on the follow-up scans.
DISCUSSION
After a total thyroidectomy, exogenous LT4 therapy for suppression of TSH and radio-iodine ablation therapy have been considered the standard treatments for DTC.[212223] These treatments reduce the risk of tumor recurrence and improve patient survival.[624] A meta-analysis by McGriff et al.[25] reported that TSH-suppressive therapy decreased the risk of major adverse clinical events, including disease progression, recurrence, and death. Despite studies showing that TSH suppressive therapy improves patient survival, there is increasing concern about the adverse effects of lifelong therapy, because DTC patients have a long life expectancy after surgery.
The critical clinical perspective on bone status has emerged largely because of the extended survival and resulted long-term subclinical hyperthyroid state. Since Ross et al.[11] reported that long-term exposure to exogenous thyroid hormone was associated with bone loss, studies had reported that TSH-suppressive therapy may cause a significant deterioration of BMD in older patients.[14262728] However, the effect of exogenous TSH-suppressive therapy remains under debate. Heemstra et al.[28] suggested that postmenopausal women undergoing long-term TSH-suppressive therapy suffer from a lower BMD and higher risk of osteoporosis compared with controls. In other studies, the change in the BMD of postmenopausal patients with DTC on suppressive therapy was unclear,[29] or there were no significant effect of long-term TSH-suppressive therapy on BMD or bone turnover markers.[3031]
The result of this study revealed the average aBMD of the patients who received TSH-suppressive therapy was not significantly decreased than that of the control group during follow-up. It coincided with report of Kim et al.[32], the study of 100 postmenopausal women and 24 premenopausal women on TSH suppression LT4 therapy, there was no significant change of BMD and bone turnover marker. The TBS decreased during the follow-up DXA evaluation over a mean of 4.02 years without statistical significance. Although there was no significant change of TBS, there was significant difference between patients and control at the time of baseline DXA measurement. One study reported that the TBS of the lumbar spine was independently and negatively correlated with the duration of TSH-suppressive therapy in DTC patients.[19] Our data were adjusted for age, BMI, and follow-up period, but we could not find the correlation between the TBS and TSH suppression duration. We expect that patients on TSH suppression will have a worse TBS at earlier period of TSH suppression, and no more aggravation after that, compared with healthy menopausal women, as described by Moon et al.[19].
DXA considered as the reference standard method for determining bone density and commonly sued way of monitoring treatment efficacy in clinical settings;[33] however, DXA has limited ability to evaluate BMD or bone quality. The TBS provides indirect indices of the trabecular microarchitecture [34] and changes prior to the T-score of DXA. TBS additive value BMDs in terms of the properties of a degraded microarchitecture of the lumbar spine than are traditional density measurements.[16] A low TBS significantly increases the risk of fragility fractures independent of BMD. [35] In particular, the TBS has been shown to be better in identifying in subjects with osteoporotic whose BMDs were normal or osteopenia on DXA with degraded microarchitecture and vertebral fractures.[17]
TSH is hypothesized to promote osteoblast differentiation by enhancing alkaline phosphatase levels and preventing bone loss, leading to skeletal remodeling and improved microarchitecture according to preclinical studies.[36] Additionally, a high level of fT4 causes skeletal toxicity, while triiodothyronine stimulates osteoclasts that increase bone turnover.[37] However, the significant difference only appeared at the early DXA measurement and there was no significant change during long term follow up period of median 4.66 years. We can infer that TSH suppression using an excessive dose of LT4 may have a negative effect on skeletal remodeling immediately after total thyroidectomy. Moreover, menopause is a major risk factor for osteoporosis. Therefore, post-menopausal women with a high-to-normal fT4 level undergoing TSH suppression with LT4 therapy experience more severe distress from a decrease in BMD in early stage of TSH suppressive therapy.
Based on our analysis, we suggest that concerns about osteoporosis in DTC patients can identify low TBS, reduce fracture risk and improve quality of life. Furthermore, we strongly advise an in-depth assessment of bone density with TBS in postmenopausal patients with DTC undergoing TSH-suppressive LT4 therapy, especially in the early stage of TSH suppressive therapy. This management process is essential because long-term TSH-suppressive LT4 therapy in postmenopausal period will unavoidably affect to further decrease in BMD.[18192838]
Our study had several limitations, including a relatively small patient population. The retrospective study design did not allow us to confirm the laboratory findings of bone turnover markers that could explain the participants' bone metabolism or to review the radiologic images for evaluation of fragility fractures during follow-up or to identify other medical history affecting bone mass and quality. Because of the critical period of bone loss starting at menopause, the unknown menopausal status during total thyroidectomy is another potential limitation.
CONCLUSIONS
In conclusion, the results of our study have clinical implications for and evaluating TBS in menopausal patients on long-term TSH-suppressive therapy. More prospective studies of TBS and its relationship with the risk of fracture, and multivariate analysis for the identification of risk factors for progression to osteoporosis, are needed to confirm our findings.
XML Download